Below are the most recent publications written about "Pleural Neoplasms" by people in Profiles.
-
Sehgal K, Gill RR, Widick P, Bindal P, McDonald DC, Shea M, Rangachari D, Costa DB. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy. JAMA Netw Open. 2021 02 01; 4(2):e2037120.
-
Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014 Nov 05; 6(261):261ra151.
-
Kruse M, Sherry SJ, Paidpally V, Mercier G, Subramaniam RM. FDG PET/CT in the management of primary pleural tumors and pleural metastases. AJR Am J Roentgenol. 2013 Aug; 201(2):W215-26.
-
Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, Churg A, Dacic S, Fraire A, Galateau-Salle F, Gibbs A, Gown A, Hammar S, Litzky L, Marchevsky AM, Nicholson AG, Roggli V, Travis WD, Wick M. Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 update of the consensus statement from the International Mesothelioma Interest Group. Arch Pathol Lab Med. 2013 May; 137(5):647-67.
-
Servais EL, Colovos C, Rodriguez L, Bograd AJ, Nitadori J, Sima C, Rusch VW, Sadelain M, Adusumilli PS. Mesothelin overexpression promotes mesothelioma cell invasion and MMP-9 secretion in an orthotopic mouse model and in epithelioid pleural mesothelioma patients. Clin Cancer Res. 2012 May 01; 18(9):2478-89.
-
Sheff KW, Hoda MA, Dome B, Hegedus B, Klepetko W, Weiss GJ. The role of microRNAs in the diagnosis and treatment of malignant pleural mesothelioma--a short review. Microrna. 2012; 1(1):40-8.
-
Servais EL, Suzuki K, Colovos C, Rodriguez L, Sima C, Fleisher M, Rusch VW, Sadelain M, Adusumilli PS. An in vivo platform for tumor biomarker assessment. PLoS One. 2011; 6(10):e26722.
-
Servais EL, Colovos C, Kachala SS, Adusumilli PS. Pre-clinical mouse models of primary and metastatic pleural cancers of the lung and breast and the use of bioluminescent imaging to monitor pleural tumor burden. Curr Protoc Pharmacol. 2011 Sep; Chapter 14:Unit14.21.
-
Shi M, Fraire AE, Chu P, Cornejo K, Woda BA, Dresser K, Rock KL, Jiang Z. Oncofetal protein IMP3, a new diagnostic biomarker to distinguish malignant mesothelioma from reactive mesothelial proliferation. Am J Surg Pathol. 2011 Jun; 35(6):878-82.
-
Gee GV, Koestler DC, Christensen BC, Sugarbaker DJ, Ugolini D, Ivaldi GP, Resnick MB, Houseman EA, Kelsey KT, Marsit CJ. Downregulated microRNAs in the differential diagnosis of malignant pleural mesothelioma. Int J Cancer. 2010 Dec 15; 127(12):2859-69.